Edition:
United Kingdom

Obalon Therapeutics Inc (OBLN.OQ)

OBLN.OQ on NASDAQ Stock Exchange Global Market

3.78USD
3:31pm BST
Change (% chg)

$0.06 (+1.61%)
Prev Close
$3.72
Open
$3.76
Day's High
$3.85
Day's Low
$3.66
Volume
2,228
Avg. Vol
57,742
52-wk High
$13.18
52-wk Low
$3.25

Chart for

About

Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in... (more)

Overall

Beta: --
Market Cap(Mil.): $58.30
Shares Outstanding(Mil.): 17.61
Dividend: --
Yield (%): --

Financials

  OBLN.OQ Industry Sector
P/E (TTM): -- 35.20 32.31
EPS (TTM): -2.08 -- --
ROI: -59.29 14.20 12.97
ROE: -69.94 16.94 14.84

BRIEF-Obalon Therapeutics Q4 Loss Per Share $0.60

* OBALON ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

05 Mar 2018

BRIEF-Obalon Therapeutics Says Audit Committee's Investigation Into Purported Whistleblower Complaint Concluded Allegations Are Meritless

* OBALON THERAPEUTICS - AUDIT COMMITTEE COMPLETED INVESTIGATION INTO PURPORTED WHISTLEBLOWER COMPLAINT; CONCLUDED ALLEGATIONS ARE MERITLESS

20 Feb 2018

Obalon cancels offering after allegation on accounting practices

Jan 23 Obalon Therapeutics Inc said on Tuesday it canceled a stock offering after the medical device maker, known for its swallowable balloons that aid in weight loss, was accused of improper accounting practices.

23 Jan 2018

BRIEF-Obalon Therapeutics prices offering of 5.5 mln shares at $5.50 per share

* OBALON THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF COMMON STOCK AT A OFFERING PRICE OF $5.50 PER SHARE​ Source text for Eikon: Further company coverage:

19 Jan 2018

BRIEF-Obalon Therapeutics Announces Proposed Public Offering Of $35 Mln Shares

* OBALON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

16 Jan 2018

BRIEF-Obalon Therapeutics Q3 loss per share $0.55

* Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

03 Nov 2017

BRIEF-Obalon Therapeutics & Sono Bello announce agreement to offer novel weight loss treatment

* Obalon Therapeutics Inc and Sono Bello announce agreement to offer novel weight loss treatment in Sono Bello centers

02 Nov 2017

BRIEF-Obalon Therapeutics files for mixed shelf of up to $100 mln

* Says in addition, selling stockholder may offer and sell up to 150,000 shares of co's common stock Source text: http://bit.ly/2z5bZGj Further company coverage:

01 Nov 2017

Earnings vs. Estimates